This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's US stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 02/14/2017. Please visit our Tracking John Paulson's Paulson & Company Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q3 2016.
This quarter, Paulson's US long portfolio decreased ~14% from $9.23B to $7.93B. There are 103 13F securities in the portfolio although only 33 of them are significantly large equity holdings (more than 0.5% of the US long portfolio). The article is focused on the larger holdings. The top five positions are Mylan Inc. (NASDAQ:MYL), Allergan plc (NYSE:AGN), Shire PLC (NASDAQ:SHPG), Teva Pharmaceutical (NYSE:TEVA), and SPDR Gold ETF (NYSEARCA:GLD) and they add up to ~43% of the portfolio. The largest holding is Mylan at ~10% of the portfolio.

